{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:30:01Z","timestamp":1772166601671,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T00:00:00Z","timestamp":1637712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T00:00:00Z","timestamp":1637712000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Public Health"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The coronavirus disease 2019 (COVID-19) vaccines can cause adverse events that can lead to vaccine hesitancy. This study aims at estimating the prevalence of severe adverse events (SAEs) and their associated factors among health professionals vaccinated with ChAdOx1 nCoV-19 vaccine in Togo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A cross-sectional study was conducted from March 13th to 19th, 2021 in Togo among health professionals who received the first dose of the vaccine. An online self-administered questionnaire was used to collect sociodemographic and vaccination data. SAEs were defined as one resulting in hospitalization, medical consultation, or inability to work the day following the administration of the vaccine. Data analysis were performed using R\u00a9 4.0.1 software, and a 5% significance level was considered.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 1,639 health professionals (70.2% male) with a median age of 32 (interquartile range: 27-40) were enrolled. At least one adverse event was reported among 71.6% of participants (95% CI = [69.3-73.8]). The most commonly reported adverse events were injection site pain (91.0%), asthenia (74.3%), headache (68.7%), soreness (55.0%), and fever (47.5%). An increased libido was also reported in 3.0% of participants. Of the participants who experienced adverse events, 18.2% were unable to go to work the day after vaccination, 10.5% consulted a medical doctor, and 1.0% were hospitalized. The SAEs\u2019 prevalence was 23.8% (95% CI = [21.8-25.9]). Being &lt;30 years (AOR = 5.54;\n                      <jats:italic>p<\/jats:italic>\n                      &lt;0.001), or 30-49 years (AOR = 3.62;\n                      <jats:italic>p<\/jats:italic>\n                      &lt;0.001) and being female (AOR = 1.97;\n                      <jats:italic>p<\/jats:italic>\n                      &lt;0.001) were associated with SAEs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>High prevalence of SAEs have been observed in health professionals in Togo after ChAdOx1 nCoV-19 vaccination especially in young people and females. However, these data are reassuring as they inform on COVID-19 vaccines\u2019 SAE management. Systematic prescription of antalgics or antipyretics could be proposed to young people who get vaccinated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13690-021-00741-x","type":"journal-article","created":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T05:02:44Z","timestamp":1637730164000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Prevalence of severe adverse events among health professionals after receiving the first dose of the ChAdOx1 nCoV-19 coronavirus vaccine (Covishield) in Togo, March 2021"],"prefix":"10.1186","volume":"79","author":[{"given":"Yao Rodion","family":"Konu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fifonsi Adjidossi","family":"Gbeasor-Komlanvi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mouhoudine","family":"Yerima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnold Junior","family":"Sadio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin Kouame","family":"Tchankoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendpouire Ida Carine","family":"Zida-Compaore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9e","family":"Nayo-Apetsianyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kossivi Agb\u00e9l\u00e9nko","family":"Afanvi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sibabe","family":"Agoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mounerou","family":"Salou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dadja Essoya","family":"Landoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atany B.","family":"Nyansa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Essohanam","family":"Boko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moustafa","family":"Mijiyawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7644-9902","authenticated-orcid":false,"given":"Didier Koumavi","family":"Ekouevi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,24]]},"reference":[{"key":"741_CR1","doi-asserted-by":"crossref","unstructured":"Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020 Feb 20;382(8):727\u201333.","DOI":"10.1056\/NEJMoa2001017"},{"key":"741_CR2","unstructured":"World Health Organization (WHO). Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV) [Internet]. [cited 2021 Mar 29]. Available from: https:\/\/www.who.int\/news\/item\/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov)."},{"key":"741_CR3","unstructured":"World Health Organization (WHO). WHO Coronavirus (COVID-19) Dashboard [Internet]. [cited 2021 Mar 24]. Available from: https:\/\/covid19.who.int"},{"key":"741_CR4","doi-asserted-by":"crossref","unstructured":"Bruinen de Bruin Y, Lequarre A-S, McCourt J, Clevestig P, Pigazzani F, Zare Jeddi M, et al. Initial impacts of global risk mitigation measures taken during the combatting of the COVID-19 pandemic. Saf Sci. 2020 Aug;128:104773.","DOI":"10.1016\/j.ssci.2020.104773"},{"key":"741_CR5","unstructured":"World Health Organization (WHO). Overview of Public Health and Social Measures in the context of COVID-19 [Internet]. [cited 2020 Jun 19]. Available from: https:\/\/www.who.int\/publications-detail-redirect\/overview-of-public-health-and-social-measures-in-the-context-of-covid-19."},{"key":"741_CR6","unstructured":"172 countries and multiple candidate vaccines engaged in COVID-19 vaccine Global Access Facility [Internet]. [cited 2021 Mar 24]. Available from: https:\/\/www.who.int\/news\/item\/24-08-2020-172-countries-and-multiple-candidate-vaccines-engaged-in-covid-19-vaccine-global-access-facility"},{"key":"741_CR7","unstructured":"World Health Organization (WHO). COVID-19 vaccines [Internet]. [cited 2021 Mar 24]. Available from: https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/covid-19-vaccines"},{"key":"741_CR8","unstructured":"World Health Organization (WHO). WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access [Internet]. [cited 2021 Mar 26]. Available from: https:\/\/www.who.int\/news\/item\/31-12-2020-who-issues-its-first-emergency-use-validation-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access"},{"key":"741_CR9","unstructured":"Global Alliance for Vacccination and Immunization (GAVI). COVAX roll-out - Togo [Internet]. [cited 2021 Mar 24]. Available from: https:\/\/www.gavi.org\/covax-vaccine-roll-out\/togo"},{"key":"741_CR10","unstructured":"Staff S. Covid-19: India looking at all \u2018serious\u2019 side effects amid safety concerns about AstraZeneca vaccine [Internet]. Scroll.in. https:\/\/scroll.in; [cited 2021 Mar 26]. Available from: https:\/\/scroll.in\/latest\/989440\/covid-19-india-looking-at-all-serious-side-effects-amid-safety-concerns-about-astrazeneca-vaccine"},{"key":"741_CR11","unstructured":"World Health Organization (WHO). WHO recommendation Serum Institute of India Pvt Ltd - COVID-19 Vaccine (ChAdOx1-S [recombinant]) - COVISHIELDTM [Internet]. WHO - Prequalification of Medical Products (IVDs, Medicines, Vaccines and Immunization Devices, Vector Control). 2021 [cited 2021 Mar 26]. Available from: https:\/\/extranet.who.int\/pqweb\/vaccines\/covid-19-vaccine-chadox1-s-recombinant-covishield"},{"key":"741_CR12","unstructured":"World Health Organization (WHO). COVID-19 national deployment and vaccination plan: Submission and review process, 29 January 2021 [Internet]. [cited 2021 Mar 30]. Available from: https:\/\/www.who.int\/publications-detail-redirect\/WHO-2019-nCoV-NDVP-country_plans-2021.1"},{"key":"741_CR13","unstructured":"R\u00e9publique Togolaise, Minist\u00e8re de la Sant\u00e9, de l\u2019Hygi\u00e8ne Publique et de l\u2019Acc\u00e8s Universel aux Soins. Epid\u00e9mie de COVID-19 au Togo-Rapport de situation N\u00b0381 au 28 mars 2021. 2021; 10p."},{"key":"741_CR14","doi-asserted-by":"crossref","unstructured":"Riad A, Sa\u011f\u0131ro\u011flu D, \u00dcst\u00fcn B, Pokorn\u00e1 A, Klugarov\u00e1 J, Attia S, et al. Prevalence and Risk Factors of CoronaVac Side Effects: An Independent Cross-Sectional Study among Healthcare Workers in Turkey. J Clin Med. 2021 Jun 15;10(12):2629.","DOI":"10.3390\/jcm10122629"},{"key":"741_CR15","doi-asserted-by":"crossref","unstructured":"Almufty HB, Mohammed SA, Abdullah AM, Merza MA. Potential adverse effects of COVID19 vaccines among Iraqi population; a comparison between the three available vaccines in Iraq; a retrospective cross-sectional study. Diabetes Metab Syndr. 2021 Jul 12;15(5):102207.","DOI":"10.1016\/j.dsx.2021.102207"},{"issue":"10267","key":"741_CR16","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","volume":"396","author":"MN Ramasamy","year":"2021","unstructured":"Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial. Lancet Lond Engl. 2021;396(10267):1979\u201393.","journal-title":"Lancet Lond Engl"},{"key":"741_CR17","doi-asserted-by":"crossref","unstructured":"Riad A, Pokorn\u00e1 A, Mekhemar M, Conrad J, Klugarov\u00e1 J, Ko\u0161\u010d\u00edk M, et al. Safety of ChAdOx1 nCoV-19 Vaccine: Independent Evidence from Two EU States. Vaccines. 2021 Jun 18;9(6):673.","DOI":"10.3390\/vaccines9060673"},{"key":"741_CR18","unstructured":"R\u00e9publique Togolaise. Minist\u00e8re de sant\u00e9, de l\u2019hygi\u00e8ne publique et de l\u2019acc\u00e8s universel aux soins. Vaccination du personnel de sant\u00e9 du pays contre la COVID-19 (Bulletin d\u2019information N\u00b02). 2021. 4p."},{"key":"741_CR19","unstructured":"R\u00e9publique Togolaise, Direction G\u00e9n\u00e9rale de la Statistique et de la Comptabilit\u00e9 Nationale du Togo (DGSCN). R\u00e9sultats d\u00e9finitifs du 4i\u00e8me Recensement G\u00e9n\u00e9ral de la Population et de l\u2019Habitat (4i\u00e8me RGPH4). Lom\u00e9: DGSCN ; 2010, 66p. Disponible sur : https:\/\/inseed.tg\/download\/2958\/."},{"key":"741_CR20","unstructured":"R\u00e9publique Togolaise. Minist\u00e8re de la sant\u00e9 de l\u2019hygi\u00e8ne publique et de l\u2019acc\u00e8s universel aux soins. Bulletin d\u2019information N\u00b03, D\u00e9ploiement des vaccins contre la COVID\u201419 au Togo. P4."},{"key":"741_CR21","unstructured":"Meo SA, Bukhari IA, Akram J, Meo AS, Klonoff DC. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer\/BioNTech and Moderna Vaccines. Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1663\u20139."},{"key":"741_CR22","unstructured":"D\u2019Alessandro D, Ciriminna S, Rossini A, Bossa MC, Fara GM. Requests of medical examinations after pneumococcal & influenza vaccination in the elderly. Indian J Med Res. 2004 May;119 Suppl:108\u201314."},{"issue":"10269","key":"741_CR23","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet Lond Engl. 2021;397(10269):99\u2013111.","journal-title":"Lancet Lond Engl"},{"key":"741_CR24","first-page":"n363","volume":"372","author":"I Torjesen","year":"2021","unstructured":"Torjesen I. Covid-19: First UK vaccine safety data are \u201creassuring,\u201d says regulator. BMJ. 2021 Feb 8;372:n363.","journal-title":"says regulator. BMJ"},{"key":"741_CR25","doi-asserted-by":"crossref","unstructured":"Bae S, Lee YW, Lim SY, Lee J-H, Lim JS, Lee S, et al. Adverse Reactions Following the First Dose of ChAdOx1 nCoV-19 Vaccine and BNT162b2 Vaccine for Healthcare Workers in South Korea. J Korean Med Sci. 2021 Apr 16;36(17):e115.","DOI":"10.3346\/jkms.2021.36.e115"},{"key":"741_CR26","doi-asserted-by":"crossref","unstructured":"Ran L, Chen X, Wang Y, Wu W, Zhang L, Tan X. Risk Factors of Healthcare Workers With Coronavirus Disease 2019: A Retrospective Cohort Study in a Designated Hospital of Wuhan in China. Clin Infect Dis Off Publ Infect Dis Soc Am. 2020 Nov 19;71(16):2218\u201321.","DOI":"10.1093\/cid\/ciaa287"},{"key":"741_CR27","doi-asserted-by":"crossref","unstructured":"Sadio AJ, Gbeasor-Komlanvi FA, Konu RY, Bakoubayi AW, Tchankoni MK, Bitty-Anderson AM, et al. Assessment of self-medication practices in the context of the COVID-19 outbreak in Togo. BMC Public Health. 2021 Jan 6;21(1):58.","DOI":"10.1186\/s12889-020-10145-1"},{"key":"741_CR28","doi-asserted-by":"crossref","unstructured":"Potluri T, Fink AL, Sylvia KE, Dhakal S, Vermillion MS, vom Steeg L, et al. Age-associated changes in the impact of sex steroids on influenza vaccine responses in males and females. Npj Vaccines. 2019 Jul 12;4(1):1\u201312.","DOI":"10.1038\/s41541-019-0124-6"},{"key":"741_CR29","doi-asserted-by":"crossref","unstructured":"Gee J. First Month of COVID-19 Vaccine Safety Monitoring \u2014 United States, December 14, 2020\u2013January 13, 2021. MMWR Morb Mortal Wkly Rep [Internet]. 2021 [cited 2021 Mar 26];70. Available from: https:\/\/www.cdc.gov\/mmwr\/volumes\/70\/wr\/mm7008e3.htm","DOI":"10.15585\/mmwr.mm7008e3"},{"key":"741_CR30","doi-asserted-by":"crossref","unstructured":"Blumenthal KG, Robinson LB, Camargo CA, Shenoy ES, Banerji A, Landman AB, et al. Acute Allergic Reactions to mRNA COVID-19 Vaccines. JAMA [Internet]. 2021 Mar 8 [cited 2021 Mar 26]; Available from: https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2777417","DOI":"10.1001\/jama.2021.3976"},{"key":"741_CR31","volume-title":"Sex Hormones and Immunity to Infection","author":"SL Klein","year":"2014","unstructured":"Klein SL, Roberts C. Sex Hormones and Immunity to Infection. Berlin, Germany: Springer Berlin; 2014."},{"key":"741_CR32","unstructured":"World Health Organization (WHO). Coronavirus disease (COVID-19): Vaccines safety [Internet]. [cited 2021 Mar 26]. Available from: https:\/\/www.who.int\/news-room\/q-a-detail\/coronavirus-disease-(covid-19)-vaccines-safety"},{"key":"741_CR33","unstructured":"US Centers for Diseases Control and Prevention (US CDC). What to Expect after Getting a COVID-19 Vaccine [Internet]. Centers for Disease Control and Prevention. 2021 [cited 2021 Mar 26]. Available from: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/expect\/after.html"},{"key":"741_CR34","unstructured":"Government of the United Kingdom. Assests publishing service. COVID-19 vaccine AstraZeneca analysis print. 2021. [Cited 26\/03\/2021]. Available from: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/972833\/COVID-19_AstraZeneca_Vaccine_Analysis_Print.pdf."},{"key":"741_CR35","unstructured":"World Health Organization (WHO). WHO statement on AstraZeneca COVID-19 vaccine safety signals [Internet]. [cited 2021 Mar 26]. Available from: https:\/\/www.who.int\/news\/item\/17-03-2021-who-statement-on-astrazeneca-covid-19-vaccine-safety-signals"}],"container-title":["Archives of Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13690-021-00741-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13690-021-00741-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13690-021-00741-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T05:07:26Z","timestamp":1637730446000},"score":1,"resource":{"primary":{"URL":"https:\/\/archpublichealth.biomedcentral.com\/articles\/10.1186\/s13690-021-00741-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,24]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["741"],"URL":"https:\/\/doi.org\/10.1186\/s13690-021-00741-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.04.20.21254863","asserted-by":"object"}]},"ISSN":["2049-3258"],"issn-type":[{"value":"2049-3258","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,24]]},"assertion":[{"value":"25 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study obtained ethical approval from the \u2018Comit\u00e9 de Bio\u00e9thique de Recherche en Sant\u00e9\u2019 (Bioethics Committee for Health Research) from the Togo Ministry of Health (No. 01\/2021\/CBRS).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests. DEL works for the World Health Organization, Togo country office. The authors are solely responsible for the views expressed in this manuscript and do not necessarily represent the decisions, policies or views of the World Health Organization.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Competing interests"}}],"article-number":"207"}}